Insider Buying: ImpediMed Limited (ASX:IPD) Insider Acquires A$13,360.87 in Stock

ImpediMed Limited (ASX:IPD) insider Christine Emmanuel-Donnelly bought 318,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average price of A$0.04 ($0.03) per share, with a total value of A$13,360.87 ($8,456.25).

ImpediMed Price Performance

The company has a market cap of $103.31 million, a P/E ratio of -5.27, a price-to-earnings-growth ratio of -102.50 and a beta of 2.86. The company has a quick ratio of 6.23, a current ratio of 6.33 and a debt-to-equity ratio of 2.81.

ImpediMed Company Profile

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.